Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial

Basit Öğe Kaydı
dc.contributor.authorOzakbas, Serkan
dc.contributor.authorTurkoglu, Recai
dc.contributor.authorTamam, Yusuf
dc.contributor.authorTerzi, Murat
dc.contributor.authorTaskapilioglu, Ozlem
dc.contributor.authorYucesan, Canan
dc.contributor.authorBaser, Hatice Limoncu
dc.date.accessioned2024-04-24T16:15:39Z
dc.date.available2024-04-24T16:15:39Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Cognitive impairment (CI) is a common problem in multiple sclerosis (MS), may occur either in early or late phase of the disease, and impairs quality of life. Objectives: This study aimed to determine the prevalence of CI and related risk factors in relapsing-remitting MS (RRMS) patients in Turkey. Methods: The present cross-sectional, multi-center, and nationally representative study included RRMS patients. Sociodemographic characteristics, cognitive functions and additional outcomes were compared between patients with and without CI. Results: The analyses included 487 RRMS patients. According to the BRB-N battery results, CI prevalence was 53.7%. There was a negative significant correlation of BRB-N subtests with age, disease duration, and EDSS and MSNQ-patient rated scores. On the logistic regression analysis, increased age, living in village/rural area, high income level, and high EDSS score were significant increasing risk factors in the development of CI. Conclusions: This is the first national cognitive data obtained from MS in Turkey, which is a country between Europe and Asia and thus has characteristics of both continents. The similarity of the results of the present study obtained from Turkey to the Western-based data indicates that CI is universal in MS and the main factors affecting CI have not changed.en_US
dc.description.sponsorshipMS Research Associationen_US
dc.description.sponsorshipThe study was funded by MS Research Association.en_US
dc.identifier.doi10.1016/j.msard.2018.03.009
dc.identifier.endpage76en_US
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid29605801
dc.identifier.scopus2-s2.0-85044620700
dc.identifier.scopusqualityQ2
dc.identifier.startpage70en_US
dc.identifier.urihttps://doi.org/10.1016/j.msard.2018.03.009
dc.identifier.urihttps://hdl.handle.net/11468/15882
dc.identifier.volume22en_US
dc.identifier.wosWOS:000433294800016
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectCognitionen_US
dc.subjectPrognosisen_US
dc.subjectPrevalenceen_US
dc.titlePrevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trialen_US
dc.titlePrevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu